Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice.
Talvard-Balland N, Braun LM, Dixon KO, Zwick M, Engel H, Hartmann A, Duquesne S, Penter L, Andrieux G, Rindlisbacher L, Acerbis A, Ehmann J, Köllerer C, Ansuinelli M, Rettig A, Moschallski K, Apostolova P, Brummer T, Illert AL, Schramm MA, Cheng Y, Köttgen A, Duyster J, Menssen HD, Ritz J, Blazar BR, Boerries M, Schmitt-Gräff A, Sariipek N, Van Galen P, Buescher JM, Cabezas-Wallscheid N, Pahl HL, Pearce EL, Soiffer RJ, Wu CJ, Vago L, Becher B, Köhler N, Wertheimer T, Kuchroo VK, Zeiser R.
Talvard-Balland N, et al. Among authors: schramm ma.
J Clin Invest. 2024 Jun 25;134(16):e177460. doi: 10.1172/JCI177460.
J Clin Invest. 2024.
PMID: 38916965
Free PMC article.